Driving liver inflammation in MASH via multiple pathways.

Metabolic dysfunction-associated steatohepatitis (MASH) if not treated early, may lead to liver cirrhosis and hepatocellular carcinoma (liver cancer).

Hepatic lipotoxicity, intestinal dysbiosis, and pro-inflammatory diets have been attributed to the development of MASH. Moreover, obesity-induced adipose tissue inflammation also contributes to MASH.

The researchers in this review unravel complex, multiple parallel inflammatory mechanisms in MASH and describe how MASH drugs exert their effects. # sciencenewshighlights ScienceMission https://sciencemission.com/liver-inflammation-in-MASH

Intra-and extrahepatic inflammation in MASH is driven by various hits such as lipotoxicity, the gut microbiome, and proinflammatory diets. Inflammation contributes to hepatic and systemic complications, including cardiovascular diseases. Beneficial drugs in MASH might target metabolic and inflammatory pathways.